Bruker Enhances Disease Research with Advanced Proteomics Tools
Event summary
- Bruker released new software updates for its timsOmni mass spectrometer to advance Functional Proteomics 2.0 workflows.
- OmniScape 2026b integrates the OmniWave algorithm for high-confidence proteoform characterization and PTM discovery.
- GlycoScape now supports eXd-enabled glycoproteomics for confident glycopeptide characterization.
- ProteoScape v2026b introduces AI-enhanced de novo peptide sequencing for database-independent proteomics.
The big picture
Bruker's updates to its proteomics tools align with the growing demand for deeper insights into disease biology and biotherapeutics development. The integration of AI and advanced algorithms positions Bruker at the forefront of the post-genomic era, where understanding proteoforms and PTMs is crucial for drug discovery and personalized medicine. The enhancements could accelerate research in immuno-oncology and other complex biological systems.
What we're watching
- Adoption Pace
- How quickly disease researchers and biotherapeutics developers will integrate these advanced proteomics tools into their workflows.
- Competitive Edge
- Whether Bruker can maintain its leadership position in proteomics with these software enhancements.
- Market Impact
- The potential influence of these advancements on the broader proteomics and disease research markets.
Related topics